Search

Your search keyword '"Auclin, Edouard"' showing total 382 results
Start Over Author "Auclin, Edouard"
382 results on '"Auclin, Edouard"'

1. Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study

Author

Flecchia, Clémence, Auclin, Edouard, Alouani, Emily, Mercier, Mathilde, Hollebecque, Antoine, Turpin, Anthony, Mazard, Thibault, Pernot, Simon, Dutherage, Marie, Cohen, Romain, Borg, Christophe, Hautefeuille, Vincent, Sclafani, Francesco, Ben-Abdelghani, Meher, Aparicio, Thomas, De La Fouchardière, Christelle, Herve, Camille, Perkins, Geraldine, Heinrich, Kathrin, Kunzmann, Volker, Gallois, Claire, Guimbaud, Rosine, Tougeron, David, and Taieb, Julien

Published
2024
Full Text
View/download PDF

2. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability

Author

Moreau, Mathilde, Alouani, Emily, Flecchia, Clémence, Falcoz, Antoine, Gallois, Claire, Auclin, Edouard, André, Thierry, Cohen, Romain, Hollebecque, Antoine, Turpin, Anthony, Pernot, Simon, Masson, Thérèse, Di Fiore, Frederic, Dutherge, Marie, Mazard, Thibault, Hautefeuille, Vincent, Van Laethem, Jean-Luc, De la Fouchardière, Christelle, Perkins, Géraldine, Ben-Abdelghani, Meher, Sclafani, Francesco, Aparicio, Thomas, Kim, Stefano, Vernerey, Dewi, Taieb, Julien, Guimbaud, Rosine, and Tougeron, David

Published
2024
Full Text
View/download PDF

3. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

Author

Riudavets, Mariona, Auclin, Edouard, Mosteiro, Miguel, Dempsey, Naomi, Majem, Margarita, Prelaj, Arsela, López-Castro, Rafael, Bosch-Barrera, Joaquim, Pilotto, Sara, Escalera, Elena, Tagliamento, Marco, Mosquera, Joaquin, Zalcman, Gérard, Aboubakar Nana, Frank, Ponce, Santiago, Albarrán-Artahona, Víctor, Dal Maso, Alessandro, Spotti, Martina, Mielgo, Xabier, Mussat, Elodie, Reyes, Roxana, Benítez, Jose-Carlos, Lupinacci, Lorena, Duchemann, Boris, De Giglio, Andrea, Blaquier, Juan Bautista, Audigier-Valette, Clarisse, Scheffler, Matthias, Nadal, Ernest, Lopes, Gilberto, Signorelli, Diego, Garcia-Campelo, Rosario, Menis, Jessica, Bluthgen, Virginia, Campayo, Marc, Recondo, Gonzalo, Besse, Benjamin, Mezquita, Laura, and Planchard, David

Published
2024
Full Text
View/download PDF

5. Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study

Author

Bergen, Elisabeth S., Pilla, Lorenzo, Auclin, Edouard, Ilhan-Mutlu, Aysegül, Prager, Gerald W., Pietrantonio, Filippo, Antista, Maria, Ghelardi, Filippo, Basile, Debora, Aprile, Giuseppe, Longarini, Raffaella, Hautefeuille, Vincent, Tougeron, David, Artru, Pascal, Mabro, May, Drouillard, Antoine, Roth, Gael, Ben Abdelghani, Meher, Clement, Inès, Toullec, Clemence, Mineur, Laurent, Guimbaud, Rosine, Taieb, Julien, and Zaanan, Aziz

Published
2023
Full Text
View/download PDF

6. Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study

Author

Baudry, Edwige, Naoun, Natacha, Auclin, Edouard, Saldana, Carolina, Barthelemy, Philippe, Geoffrois, Lionnel, Thibault, Constance, de Vries-Brilland, Manon, Borchiellini, Delphine, Maillet, Denis, Hirsch, Laure, Vauchier, Charles, Carril-Ajuria, Lucia, Colomba, Emeline, Bernard-Tessier, Alice, Escudier, Bernard, Flippot, Ronan, and Albigès, Laurence

Published
2023
Full Text
View/download PDF

9. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort

Author

Taïeb, Julien, Sayah, Lina, Heinrich, Kathrin, Kunzmann, Volker, Boileve, Alice, Cirkel, Geert, Lonardi, Sara, Chibaudel, Benoist, Turpin, Anthony, Beller, Tamar, Hautefeuille, Vincent, Vivaldi, Caterina, Mazard, Thibault, Bauguion, Lucile, Niger, Monica, Prager, Gerald W., Coutzac, Clelia, Benedikt Westphalen, C., Auclin, Edouard, and Pilla, Lorenzo

Published
2023
Full Text
View/download PDF

10. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24)

Author

Thibault, Constance, Fléchon, Aude, Albiges, Laurence, Joly, Charlotte, Barthelemy, Philippe, Gross-Goupil, Marine, Chevreau, Christine, Coquan, Elodie, Rolland, Frédéric, Laguerre, Brigitte, Gravis, Gwenaelle, Pécuchet, Nicolas, Elaidi, Réza-Thierry, Timsit, Marc-Olivier, Brihoum, Meryem, Auclin, Edouard, de Reyniès, Aurélien, Allory, Yves, and Oudard, Stéphane

Published
2023
Full Text
View/download PDF

12. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

Author

Auclin, Edouard, Benitez-Montanez, Jose, Tagliamento, Marco, Parisi, Francesca, Gorria, Teresa, Garcia-Campelo, Rosario, Dempsey, Naomi, Pinato, David J., Reyes, Roxana, Albarrán-Artahona, Víctor, Dall'Olio, Filippo, Soldato, Davide, Hendriks, Lizza, Nana, Frank Aboubakar, Tonneau, Marion, Lopez-Castro, Rafael, Nadal, Ernest, Kazandjian, Suzanne, Muanza, Thierry, Blanc-Durand, Félix, Fabre, Elizabeth, Castro, Natalia, Arasanz, Hugo, Rochand, Adrien, Besse, Benjamin, Routy, Bertrand, and Mezquita, Laura

Published
2023
Full Text
View/download PDF

17. Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer

Author

Riudavets, Mariona, Lamberts, Virginie, Vasseur, Damien, Auclin, Edouard, Aldea, Mihaela, Jovelet, Cécile, Naltet, Charles, Lavaud, Pernelle, Gazzah, Anas, Aboubakar, Frank, Dorta, Miriam, Remon, Jordi, Rouleau, Etienne, Ngocamus, Maud, Nicotra, Claudio, Lacroix, Ludovic, Besse, Benjamin, Mezquita, Laura, and Planchard, David

Published
2022
Full Text
View/download PDF

18. First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study

Author

Gallois, Claire, Hafliger, Emilie, Auclin, Edouard, Perret, Audrey, Coutzac, Clélia, Turpin, Anthony, Pellat, Anna, Randrian, Violaine, Basile, Debora, Faroux, Roger, Pernot, Simon, Locher, Christophe, Hautefeuille, Vincent, Dubreuil, Olivier, Palmieri, Lola-Jade, Dior, Marie, Artru, Pascal, and Taieb, Julien

Published
2022
Full Text
View/download PDF

19. A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial.

Author

Samaille, Thomas, Falcoz, Antoine, Cohen, Romain, Laurent-Puig, Pierre, André, Thierry, Taieb, Julien, Auclin, Edouard, and Vernerey, Dewi

Subjects
RISK assessment, PREDICTIVE tests, DATA analysis, T-test (Statistics), STATISTICAL significance, FISHER exact test, RETROSPECTIVE studies, MULTIVARIATE analysis, TUMOR markers, CHI-squared test, DESCRIPTIVE statistics, COLON tumors, KAPLAN-Meier estimator, NUCLEIC acids, MEDICAL records, ACQUISITION of data, STATISTICS, TUMOR antigens, EXTRACELLULAR space, TUMOR classification, PROGRESSION-free survival, CONFIDENCE intervals, POSTOPERATIVE period, DATA analysis software, PROPORTIONAL hazards models, BLOOD, DISEASE risk factors
Abstract

Background We assessed the added value of incorporating carcinoembryonic antigen (CEA) to circulating tumor DNA (ctDNA) and pathological TN (pTN) stage for risk classification in stage 3 colon cancer (CC). Patients and Methods We retrospectively analyzed postoperative CEA values in patients with CC from the IDEA-France phase 3 trial. The relation between disease-free survival (DFS) and CEA was modeled through restricted cubic splines. Prognostic value of CEA, ctDNA, and pTN was assessed with the Kaplan-Meier method. Multivariate analysis was used to identify prognostic and predictive factors for DFS. Results Among 696 patients (35%), CEA values were retrievable, and for 405 (20%) both CEA and ctDNA were available. An optimized CEA threshold of 2 ng/mL was identified, the 3-year DFS was 66.4% for patients above the threshold and 80.9% for those below (HR, 1.74; 95% CI, 1.33-2.28, P  < .001). In multivariate analysis, CEA ≥ 2 ng/mL contributed significantly to model variability, becoming an independent prognostic factor for DFS (HR, 1.82; 95% CI,1.27-2.59), alongside ctDNA (HR, 1.88; 95% CI, 1.16-3.03) and pTN (HR, 1.78; 95% CI, 1.24-2.54). A novel integrated risk classification combining CEA, ctDNA, and pTN stage reclassified 19.8% of pT4/N2 patients as low risk and 2.5% of pT3/N1 patients as high risk. This new classification demonstrated the 3-year DFS of 80.8% for low-risk patients and 55.4% for high-risk patients (HR, 2.66, 95% CI, 1.84-3.86, P  < .001). Conclusions Postoperative CEA value is a prognostic factor for DFS in stage 3 CC, independently of ctDNA and pTN. It advocates for systematic reporting in future adjuvant trials. Integrating both biomarkers with pTN could refine risk classification in stage 3 CC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

Author

Seguí, Elia, Torres, Juan Manuel, Auclin, Edouard, Casadevall, David, Peiro Carmona, Sara, Aguilar-Company, Juan, García de Herreros, Marta, Gorría, Teresa, Laguna, Juan Carlos, Rodríguez, Marta, González, Azucena, Epaillard, Nicolas, Gavira, Javier, Bolaño, Victor, Tapia, Jose C., Tagliamento, Marco, Teixidó, Cristina, Arasanz, Hugo, Pilotto, Sara, and Lopez-Castro, Rafael

Subjects
NEUTROPHIL lymphocyte ratio, RESEARCH funding, NEUTROPHILS, CANCER patients, RETROSPECTIVE studies, DESCRIPTIVE statistics, SEVERITY of illness index, TUMOR markers, TREATMENT effectiveness, LONGITUDINAL method, RESEARCH, MEDICAL records, ACQUISITION of data, TUMORS, INFLAMMATION, CYTOKINES, COVID-19, BIOMARKERS, INTERLEUKINS, DISEASE complications
Abstract

Simple Summary: Understanding the inflammatory interplay between cancer and COVID-19 infection is essential for improving patient care. Our study bridges a vital knowledge gap by exploring how a pre-existing tumor-induced inflammatory state can exacerbate the inflammatory response to COVID-19, adversely impacting COVID-19 outcomes. We introduce the FLARE score, a robust predictor derived from circulating inflammatory markers, that provides clinicians a practical tool for early identification of patients with cancer at higher risk of severe COVID-19 complications who might benefit most from immediate and intensive treatment strategies. Additionally, our study also underscore the role of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease. Purpose: Inflammation and neutrophils play a central role in both COVID-19 disease and cancer. We aimed to assess the impact of pre-existing tumor-related inflammation on COVID-19 outcomes in patients with cancer and to elucidate the role of circulating neutrophil subpopulations. Methods: We conducted a multicenter retrospective analysis of 524 patients with cancer and SARS-CoV-2 infection, assessing the relationship between clinical outcomes and circulating inflammatory biomarkers collected before and during COVID-19 infection. Additionally, a single-center prospective cohort study provided data for an exploratory analysis, assessing the immunophenotype of circulating neutrophils and inflammatory cytokines. The primary endpoints were 30-day mortality and the severity of COVID-19 disease. Results: Prior to COVID-19, 25% of patients with cancer exhibited elevated dNLR, which increased to 55% at the time of COVID-19 diagnosis. We developed the FLARE score, incorporating both tumor- and infection-induced inflammation, which categorized patients into four prognostic groups. The poor prognostic group had a 30-day mortality rate of 68%, significantly higher than the 23% in the favorable group (p < 0.0001). This score proved to be an independent predictor of early mortality. This prospective analysis revealed a shift towards immature forms of neutrophils and higher IL-6 levels in patients with cancer and severe COVID-19 infection. Conclusions: A pre-existing tumor-induced pro-inflammatory state significantly impacts COVID-19 outcomes in patients with cancer. The FLARE score, derived from circulating inflammatory markers, emerges as an easy-to-use, globally accessible, effective tool for clinicians to identify patients with cancer at heightened risk of severe COVID-19 complications and early mortality who might benefit most from immediate and intensive treatment strategies. Furthermore, our findings underscore the significance of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort

Author

Auclin, Edouard, Marthey, Lysiane, Abdallah, Raef, Mas, Léo, Francois, Eric, Saint, Angélique, Cunha, Antonio Sa, Vienot, Angélique, Lecomte, Thierry, Hautefeuille, Vincent, de La Fouchardière, Christelle, Sarabi, Matthieu, Ksontini, Feryel, Forestier, Julien, Coriat, Romain, Fabiano, Emmanuelle, Leroy, Florence, Williet, Nicolas, Bachet, Jean-Baptiste, Tougeron, David, and Taieb, Julien

Published
2021
Full Text
View/download PDF

22. CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17

Author

Corgnac, Stéphanie, Malenica, Ines, Mezquita, Laura, Auclin, Edouard, Voilin, Elodie, Kacher, Jamila, Halse, Heloise, Grynszpan, Laetitia, Signolle, Nicolas, Dayris, Thibault, Leclerc, Marine, Droin, Nathalie, de Montpréville, Vincent, Mercier, Olaf, Validire, Pierre, Scoazec, Jean-Yves, Massard, Christophe, Chouaib, Salem, Planchard, David, Adam, Julien, Besse, Benjamin, and Mami-Chouaib, Fathia

Published
2020
Full Text
View/download PDF

23. Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

Author

Aldea, Mihaela, Hendriks, Lizza, Mezquita, Laura, Jovelet, Cécile, Planchard, David, Auclin, Edouard, Remon, Jordi, Howarth, Karen, Benitez, Jose Carlos, Gazzah, Anas, Lavaud, Pernelle, Naltet, Charles, Lacroix, Ludovic, de Kievit, Frank, Morris, Clive, Green, Emma, Ngo-Camus, Maud, Rouleau, Etienne, Massard, Christophe, Caramella, Caroline, Friboulet, Luc, and Besse, Benjamin

Published
2020
Full Text
View/download PDF

27. Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Author

Hendriks, Lizza E.L., Henon, Clemence, Auclin, Edouard, Mezquita, Laura, Ferrara, Roberto, Audigier-Valette, Clarisse, Mazieres, Julien, Lefebvre, Corentin, Rabeau, Audrey, Le Moulec, Sylvestre, Cousin, Sophie, Duchemann, Boris, le Pechoux, Cecile, Botticella, Angela, Ammari, Samy, Gazzah, Anas, Caramella, Caroline, Adam, Julien, Lechapt, Emmanuèle, Planchard, David, De Ruysscher, Dirk, Dingemans, Anne-Marie, and Besse, Benjamin

Published
2019
Full Text
View/download PDF

29. Association between Lung Immune Prognostic Index and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer

Author

Riudavets, Mariona, primary, Auclin, Edouard, additional, Mosteiro, Miguel, additional, Dempsey, Naomi, additional, Majem, Margarita, additional, Prelaj, Arsela, additional, López-Castro, Rafael, additional, Bosch-Barrera, Joaquim, additional, Pilotto, Sara, additional, Escalera, Elena, additional, Tagliamento, Marco, additional, Mosquera, Joaquin, additional, Zalcman, Gérard, additional, Nana, Frank Aboubakar, additional, Ponce, Santiago, additional, Albarrán-Artahona, Víctor, additional, Maso, Alessandro Dal, additional, Spotti, Martina, additional, Mielgo, Xabier, additional, Mussat, Elodie, additional, Reyes, Roxana, additional, Benítez, Jose-Carlos, additional, Lupinacci, Lorena, additional, Duchemann, Boris, additional, De Giglio, Andrea, additional, Blaquier, Juan Bautista, additional, Audigier-Valette, Clarisse, additional, Scheffler, Matthias, additional, Nadal, Ernest, additional, Lopes, Gilberto, additional, Signorelli, Diego, additional, Garcia-Campelo, Rosario, additional, Menis, Jessica, additional, Bluthgen, Virginia, additional, Campayo, Marc, additional, Recondo, Gonzalo, additional, Besse, Benjamin, additional, Mezquita, Laura, additional, and Planchard, David, additional

Published
2023
Full Text
View/download PDF

30. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Author

Chour, Ali, primary, Denis, Julie, additional, Mascaux, Céline, additional, Zysman, Maeva, additional, Bigay-Game, Laurence, additional, Swalduz, Aurélie, additional, Gounant, Valérie, additional, Cortot, Alexis, additional, Darrason, Marie, additional, Fallet, Vincent, additional, Auclin, Edouard, additional, Basse, Clémence, additional, Tissot, Claire, additional, Decroisette, Chantal, additional, Bombaron, Pierre, additional, Giroux-Leprieur, Etienne, additional, Odier, Luc, additional, Brosseau, Solenn, additional, Creusot, Quentin, additional, Gueçamburu, Marina, additional, Meersseman, Corentin, additional, Rochand, Adrien, additional, Costantini, Adrien, additional, Gaillard, Claire Marine, additional, Wasielewski, Eric, additional, Girard, Nicolas, additional, Cadranel, Jacques, additional, Lafitte, Claire, additional, Lebossé, Fanny, additional, and Duruisseaux, Michaël, additional

Published
2023
Full Text
View/download PDF

37. Table S3 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Author

Ferrara, Roberto, primary, Naigeon, Marie, primary, Auclin, Edouard, primary, Duchemann, Boris, primary, Cassard, Lydie, primary, Jouniaux, Jean-Mehdi, primary, Boselli, Lisa, primary, Grivel, Jonathan, primary, Desnoyer, Aude, primary, Mezquita, Laura, primary, Texier, Matthieu, primary, Caramella, Caroline, primary, Hendriks, Lizza, primary, Planchard, David, primary, Remon, Jordi, primary, Sangaletti, Sabina, primary, Proto, Claudia, primary, Garassino, Marina C., primary, Soria, Jean-Charles, primary, Marabelle, Aurelien, primary, Voisin, Anne-Laure, primary, Farhane, Siham, primary, Besse, Benjamin, primary, and Chaput, Nathalie, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Methods from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Author

Ferrara, Roberto, primary, Naigeon, Marie, primary, Auclin, Edouard, primary, Duchemann, Boris, primary, Cassard, Lydie, primary, Jouniaux, Jean-Mehdi, primary, Boselli, Lisa, primary, Grivel, Jonathan, primary, Desnoyer, Aude, primary, Mezquita, Laura, primary, Texier, Matthieu, primary, Caramella, Caroline, primary, Hendriks, Lizza, primary, Planchard, David, primary, Remon, Jordi, primary, Sangaletti, Sabina, primary, Proto, Claudia, primary, Garassino, Marina C., primary, Soria, Jean-Charles, primary, Marabelle, Aurelien, primary, Voisin, Anne-Laure, primary, Farhane, Siham, primary, Besse, Benjamin, primary, and Chaput, Nathalie, primary

Published
2023
Full Text
View/download PDF

39. Figure S4 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Author

Ferrara, Roberto, primary, Naigeon, Marie, primary, Auclin, Edouard, primary, Duchemann, Boris, primary, Cassard, Lydie, primary, Jouniaux, Jean-Mehdi, primary, Boselli, Lisa, primary, Grivel, Jonathan, primary, Desnoyer, Aude, primary, Mezquita, Laura, primary, Texier, Matthieu, primary, Caramella, Caroline, primary, Hendriks, Lizza, primary, Planchard, David, primary, Remon, Jordi, primary, Sangaletti, Sabina, primary, Proto, Claudia, primary, Garassino, Marina C., primary, Soria, Jean-Charles, primary, Marabelle, Aurelien, primary, Voisin, Anne-Laure, primary, Farhane, Siham, primary, Besse, Benjamin, primary, and Chaput, Nathalie, primary

Published
2023
Full Text
View/download PDF

42. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study

Author

Alouani, Emily, Mercier, Mathilde, Flecchia, Clémence, Auclin, Edouard, Hollebecque, Antoine, Mazard, Thibault, Turpin, Anthony, Pernot, Simon, Cohen, Romain, Dutherage, Marie, Kim, S., Sclafani, Francesco, Ben-Abdelghani, Méher, Herve, Camille, Aparicio, Thomas, De La Fouchardière, Christelle, Perkins, Géraldine, Hautefeuille, Vincent, Jaffrelot, Marion, Gallois, Claire, Bongard, Vanina, Tougeron, David, Taieb, Julien, Guimbaud, Rosine, Alouani, Emily, Mercier, Mathilde, Flecchia, Clémence, Auclin, Edouard, Hollebecque, Antoine, Mazard, Thibault, Turpin, Anthony, Pernot, Simon, Cohen, Romain, Dutherage, Marie, Kim, S., Sclafani, Francesco, Ben-Abdelghani, Méher, Herve, Camille, Aparicio, Thomas, De La Fouchardière, Christelle, Perkins, Géraldine, Hautefeuille, Vincent, Jaffrelot, Marion, Gallois, Claire, Bongard, Vanina, Tougeron, David, Taieb, Julien, and Guimbaud, Rosine

Abstract

Background: Immunotherapy demonstrated remarkable efficacy in metastatic colorectal cancers (mCRCs) with mismatch repair deficiency (MMRd)/microsatellite instability (MSI). However, data regarding efficacy and safety of immunotherapy in the routine clinical practice are scarce. Patients and methods: This is a retrospective, multicenter study aiming to evaluate efficacy and safety of immunotherapy in routine clinical practice and to identify predictive markers for long-term benefit. Long-term benefit was defined as progression-free survival (PFS) exceeding 24 months. All patients who received immunotherapy for an MMRd/MSI mCRC were included. Patients who received immunotherapy in combination with another known effective therapeutic class agent (chemotherapy or tailored therapy) were excluded. Results: Overall, 284 patients across 19 tertiary cancer centers were included. After a median follow-up of 26.8 months, the median overall survival (mOS) was 65.4 months [95% confidence interval (CI) 53.8 months-not reached (NR)] and the median PFS (mPFS) was 37.9 months (95% CI 30.9 months-NR). There was no difference in terms of efficacy or toxicity between patients treated in the real-world or as part of a clinical trial. Overall, 46.6% of patients had long-term benefit. Independent markers associated with long-term benefit were Eastern Cooperative Oncology Group-performance status (ECOG-PS) 0 (P = 0.025) and absence of peritoneal metastases (P = 0.009). Conclusions: Our study confirms the efficacy and safety of immunotherapy in patients with advanced MMRd/MSI CRC in the routine clinical practice. ECOG-PS score and absence of peritoneal metastases provide simple markers that could help identify patients who benefit the most from this treatment., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

43. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma

Author

Parent, Pauline, primary, Auclin, Edouard, additional, Patrikidou, Anna, additional, Mezquita, Laura, additional, Martínez Chanzá, Nieves, additional, Dumont, Clément, additional, Rodriguez-Vida, Alejo, additional, Llacer, Casilda, additional, Lozano, Rebeca, additional, Ratta, Raffaele, additional, Merseburger, Axel S., additional, Sternberg, Cora N., additional, Baciarello, Giulia, additional, Colomba, Emeline, additional, Fuerea, Alina, additional, Besse, Benjamin, additional, Loriot, Yohann, additional, and Lavaud, Pernelle, additional

Published
2023
Full Text
View/download PDF

45. Gemcitabine Plus Platinum-Based Chemotherapy in Combination with Bevacizumab for Kidney Metastatic Collecting Duct and Medullary Carcinomas: Results of a Prospective Phase II Trial (BEVABEL- GETUG/AFU24)

Author

Thibault, Constance, primary, Flechon, Aude, additional, ALBIGES, Laurence, additional, JOLY, Charlotte, additional, BARTHELEMY, Philippe, additional, Gross-Goupil, Marine, additional, Chevreau, Christine, additional, Coquan, Elodie, additional, Rolland, Frédéric, additional, Laguerre, Brigitte, additional, Gravis, Gwenaëlle, additional, Pecuchet, Nicolas, additional, Elaidi, Rea-Thierry, additional, Timsit, Marc-Olivier, additional, Brihoum, Meryem, additional, AUCLIN, Edouard, additional, De Reynies, Aurélien, additional, Allory, Yves, additional, and OUDARD, Stéphane, additional

Published
2023
Full Text
View/download PDF

48. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score

Author

Pierro, Monica, primary, Baldini, Capucine, additional, Auclin, Edouard, additional, Vincent, Hélène, additional, Varga, Andreea, additional, Martin Romano, Patricia, additional, Vuagnat, Perrine, additional, Besse, Benjamin, additional, Planchard, David, additional, Hollebecque, Antoine, additional, Champiat, Stéphane, additional, Marabelle, Aurélien, additional, Michot, Jean-Marie, additional, Massard, Christophe, additional, and Mezquita, Laura, additional

Published
2022
Full Text
View/download PDF

50. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Author

Mezquita, Laura, Auclin, Edouard, Ferrara, Roberto, Charrier, Melinda, Remon, Jordi, Planchard, David, Ponce, Santiago, Ares, Luis Paz, Leroy, Laura, Audigier-Valette, Clarisse, Felip, Enriqueta, Zerón-Medina, Jorge, Garrido, Pilar, Brosseau, Solenn, Zalcman, Gérard, Mazieres, Julien, Caramela, Caroline, Lahmar, Jihene, Adam, Julien, Chaput, Nathalie, Soria, Jean Charles, and Besse, Benjamin

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results